CD98 heavy chain protein is overexpressed in non-small cell lung cancer and is a potential target for CAR T-cell therapy
Moto Yaga,Kana Hasegawa,Shunya Ikeda,Miwa Matsubara,Takashi Hiroshima,Toru Kimura,Yuya Shirai,Wibowo Tansri,Hirofumi Uehara,Mana Tachikawa,Yuzuru Okairi,Masayuki Sone,Hiromi Mori,Yosuke Kogue,Hiroki Akamine,Daisuke Okuzaki,Kotaro Kawagishi,Satoshi Kawanaka,Hiroyuki Yamato,Yukiyasu Takeuchi,Eiji Okura,Ryu Kanzaki,Jiro Okami,Itsuko Nakamichi,Shigeru Nakane,Aki Kobayashi,Takashi Iwazawa,Toshiteru Tokunaga,Hideoki Yokouchi,Yukihiro Yano,Junji Uchida,Masahide Mori,Kiyoshi Komuta,Tetsuro Tachi,Hideki Kuroda,Noriyuki Kijima,Haruhiko Kishima,Michiko Ichii,Shinji Futami,Yujiro Naito,Takayuki Shiroyama,Kotaro Miyake,Shohei Koyama,Haruhiko Hirata,Yoshito Takeda,Soichiro Funaki,Yasushi Shintani,Atsushi Kumanogoh,Naoki Hosen
DOI: https://doi.org/10.1038/s41598-024-68779-9
IF: 4.6
2024-08-04
Scientific Reports
Abstract:Chimeric antigen receptor (CAR) T cells are effective against hematological cancers, but are less effective against solid tumors such as non-small cell lung cancer (NSCLC). One of the reasons is that only a few cell surface targets specific for NSCLC cells have been identified. Here, we report that CD98 heavy chain (hc) protein is overexpressed on the surface of NSCLC cells and is a potential target for CAR T cells against NSCLC. Screening of over 10,000 mAb clones raised against NSCLC cell lines showed that mAb H2A011 bound to NSCLC cells but not normal lung epithelial cells. H2A011 recognized CD98hc. Although CAR T cells derived from H2A011 could not be established presumably due to the high level of H2A011 reactivity in activated T cells, those derived from the anti-CD98hc mAb R8H283, which had been shown to lack reactivity with CD98hc glycoforms expressed on normal hematopoietic cells and some normal tissues, were successfully developed. R8H283 specifically reacted with NSCLC cells in six of 15 patients. R8H283-derived CAR T cells exerted significant anti-tumor effects in a xenograft NSCLC model in vivo. These results suggest that R8H283 CAR T cells may become a new therapeutic tool for NSCLC, although careful testing for off-tumor reactivity should be performed in the future.
multidisciplinary sciences